doctor reddy's lab-adr (RDY:New York)
doctor reddy's lab-adr (RDY) Snapshot
|
Open
$35.99
|
Previous Close
$36.71
|
|
|
Day High
$36.52
|
Day Low
$35.64
|
|
|
52 Week High
05/16/13 - $38.74
|
52 Week Low
06/25/12 - $27.36
|
|
|
Market Cap
6.1B
|
Average Volume 10 Days
172.3K
|
|
|
EPS TTM
--
|
Shares Outstanding
169.9M
|
|
|
EX-Date
07/10/13
|
P/E TM
--
|
|
|
Dividend
$0.26
|
Dividend Yield
0.69%
|
Related News
doctor reddy's lab-adr (RDY) Related Businessweek News
No Related Businessweek News Founddoctor reddy's lab-adr (RDY) Details
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. It offers a range of APIs for use in amyotrophic lateral sclerosis, anti-inflammatory, anti-allergic, anti-asthmatic, anticoagulant, anti-convulsant, anti-diabetic, anti-emetic, anti-fungal, anti-gout, anti-migraine, ARV and anti-viral, benign prostate hyperlasia, cardiovascular, erectile dysfunction, expectorant, expectorant, gastro-intestinal, genitourinary, hyperparathyroidism, immunology and inflammation, multiple sclerosis, muscle relaxant, neuropsychiatry, oncology, ophthalmic, osteoporosis, steroid, and urinary incontinence products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. It offers a portfolio of branded generics in the therapeutic areas of gastro-intestinal, cardiovascular, central nervous system, pain management, oncology, anti-infective, hormones, urology, respiratory, gynecology, pediatrics, and dermatology. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. This segment also focuses on developing differentiated formulations and biosimilars. The company primarily operates in India, the United States, Russia and other CIS countries, Germany, the United Kingdom, Venezuela, South Africa, Romania, and New Zealand. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
doctor reddy's lab-adr (RDY) Top Compensated Officers
doctor reddy's lab-adr (RDY) Key Developments
Fujifilm Co. Ltd. and Dr. Reddy's Laboratories Ltd. have decided to terminate the Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan. Based on the Memorandum of Understanding signed on July 28, 2011, the two companies had conducted detailed studies on the establishment of a joint venture for developing and manufacturing generic drugs in Japan. However, as Fujifilm realigns its long-term growth strategy for the pharmaceutical business, both companies have led to a mutual agreement to terminate the Memorandum of Understanding. The two companies will continue to explore partnership/alliance opportunities in other pharmaceutical businesses such as API (active pharmaceutical ingredient) development and manufacturing, contract research and development and manufacturing, and the development and marketing of super-generics.
Fresenius Kabi has dragged Dr. Reddy's Laboratories to court for allegedly infringing on the former's patented injected anaesthetic Diprivan on four counts. Diprivan (propofol) is an injectable general anaesthetic for the induction and maintenance of anaesthesia and can also be used for inducing sedating in ventilated patients and those undergoing diagnostic or surgical procedures. In a petition filed against DRL in U.S. District Court of Delaware, Fresenius said it held an approved New Drug Application (NDA) No. 19627 under section 505(b) of the Federal Food, Drug and Cosmetic Act. Dr. Reddy's officials declined to comment on the issue. The petition said DRL filed an Abbreviated New Drug Application (ANDA) with the U.S. regulator seeking approval to manufacture, use, offer for sale, sell in and import into the U.S. a Propofol injectable even before the expiration of the patent.
Dr. Reddy's Laboratories Ltd., Board Meeting, May 13, 2013. Agenda: To consider grant of stock options.
| Recently Viewed | |||
| RDY:US | $35.64 USD | -1.07 |  |
| Company | Last | Change |
| Cipla Ltd/India | 379.00 INR | -0.50 |
| Lupin Ltd | 780.15 INR | -15.10 |
| Ranbaxy Laboratories Ltd | 348.20 INR | -6.00 |
| Sigma-Aldrich Corp | $81.19 USD | -0.99 |
| Stada Arzneimittel AG | €33.40 EUR | -0.38 |
| View Industry Companies | ||
Industry Analysis
RDY
Industry Average
| Valuation | RDY | Industry Range |
| Price/Earnings | 20.0x |
|
| Price/Sales | 2.9x |
|
| Price/Book | 4.6x |
|
| Price/Cash Flow | 19.9x |
|
| TEV/Sales | 2.4x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
